2026 ASCO Lung Cancer Living Guideline: New First-Line Treatment for Stage IV NSCLC

By Editorial Team

Quick Summary & Core Update

The American Society of Clinical Oncology (ASCO) has released its updated 2026 Living Guideline for Stage IV Non-Small Cell Lung Cancer (NSCLC) Without Driver Alterations. The major takeaway is the addition of retifanlimab-dlwr (an immunotherapy drug sold under the brand name ZYNYZ) combined with standard chemotherapy as a highly effective first-line treatment option. Clinical trial data shows that adding this drug significantly extends survival and stalls cancer growth compared to chemotherapy alone.

When dealing with a diagnosis of Stage IV Non-Small Cell Lung Cancer (NSCLC), timing and precision are everything. Because lung cancer research moves incredibly fast, medical organizations utilize what are known as "Living Guidelines"—clinical roadmaps that experts update continuously as soon as groundbreaking clinical trial data breaks.

The latest version, published in the Journal of Clinical Oncology, delivers vital new options for patients whose cancers do not have driver alterations. Driver alterations are specific genetic mutations (like EGFR, ALK, ROS1, or BRAF) that act as "on switches" for cancer growth. When a patient is negative for these switches, traditional targeted pills won't work, making immunotherapy and chemotherapy the main treatments.

Here is what patients, families, and care advocates need to know about the new medical standards.

The Core Update: Retifanlimab Plus Chemotherapy

The ASCO expert panel has officially added the intravenous drug retifanlimab to the approved arsenal of first-line treatment combinations. Retifanlimab is a PD-1 inhibitor, a type of immunotherapy that works by unmasking cancer cells so your body's natural immune system can locate and destroy them.

According to the new rules, doctors can offer this treatment to patients who have:

  • Good physical performance status (the patient is strong enough to handle daily activities).
  • Nonsquamous or squamous cell types of advanced lung cancer.
  • Any level of PD-L1 expression (a protein marker that helps predict how well a patient might respond to immunotherapy).

What the Data Shows: The POD1UM-304 Trial

Medical guidelines change only when data overwhelmingly proves a new strategy is superior. This recommendation is built on the rigorous Phase 3 POD1UM-304 clinical trial, which followed 583 previously untreated patients.

The study compared patients receiving retifanlimab paired with platinum-based chemotherapy against those receiving a placebo with chemotherapy. The results were clear:

Clinical Metric Standard Chemotherapy Alone New: Retifanlimab + Chemotherapy
Median Overall Survival 13.4 months 18.1 months
Progression-Free Survival 5.5 months 7.7 months
Objective Response Rate 39% 52%
Duration of Response 6.1 months 12.7 months

Essentially, adding retifanlimab extended average survival by nearly five months and more than doubled the length of time patients stayed in a stable, responsive state.

Understanding Side Effects & Safety

Every active medical treatment carries tradeoffs. Patients adding retifanlimab did report slightly higher rates of anemia (low red blood cell count) (63% vs 58%) and decreased appetite.

However, the combination surprisingly showed fewer issues with liver enzyme spikes and less overall nausea than the chemotherapy-only group, indicating a manageable safety profile for most individuals.

Crucial Context for Brain Metastases

Lung cancer frequently spreads to the brain, which requires specialized treatment management. The ASCO panel thoroughly reviewed data from the BAP BRAIN trial, which evaluated adding an anti-blood-vessel drug called bevacizumab to chemotherapy for patients with untreated, silent brain metastases.

Key Takeaway: While the brain-specific study was positive, ASCO did not change its broad first-line standard because modern immunotherapy remains the superior primary standard of care. However, if a patient is medically ineligible for immunotherapy, this trial provides robust backup evidence for using a bevacizumab-chemotherapy mix to control brain progression.

Questions to Take to Your Oncology Appointment

If you or a family member are mapping out a first-line treatment plan for advanced non-small cell lung cancer, consider discussing these exact points with your treatment team:

  1. Have we completely ruled out driver alterations (like EGFR or ALK mutations) via comprehensive biomarker testing?
  2. Given the 2026 ASCO update, would retifanlimab combined with chemotherapy be an appropriate frontline treatment option for my case?
  3. What are the institutional availability and insurance coverage paths for this specific immunotherapy regimen versus standard options like pembrolizumab?

Frequently Asked Questions (FAQ)

What is the 2026 ASCO Living Guideline for Stage IV NSCLC without driver alterations?

It is a continually updated medical blueprint from cancer experts outlining standard treatments for advanced lung cancer lacking targetable genetic mutations. The May 2026 update adds the PD-1 immunotherapy drug retifanlimab-dlwr combined with chemotherapy to the standard choice menu.

What is retifanlimab and how does it treat lung cancer?

Retifanlimab is an immune checkpoint inhibitor (specifically a PD-1 monoclonal antibody). It blocks a pathway that cancer cells use to hide from your body's immune defenses, enabling your natural T-cells to identify, target, and kill the cancer cells effectively.

Does the new combination improve survival stats?

Yes. Data from the Phase 3 POD1UM-304 trial showed that adding retifanlimab to standard platinum chemotherapy increased median overall survival to 18.1 months, compared to just 13.4 months for chemotherapy alone.

Disclaimer: This article is a layman-focused editorial summary of the ASCO Clinical Practice Living Guideline (Version 2026.3.1). It is provided strictly for educational purposes and is not a substitute for direct medical counseling or treatment determinations from qualified oncology specialists.

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2026 Update)

By Editorial Team
Image
Ivermectin is a drug primarily used to treat parasitic infections, and it has attracted research interest for its potential biological effects in cancer models, particularly within integrative and experimental treatment contexts. Supporters point to hundreds of preclinical studies and case reports showing anti-tumor activity across multiple cancer types.  However, current mainstream oncology guidelines do not support ivermectin as a standard or evidence-based treatment for cancer, especially as a substitute for established therapies such as immunotherapy, targeted therapy, chemotherapy, or radiotherapy. So where does the truth lie? The answer is more nuanced than either side often suggests. Access to modern cancer care remains uneven globally. Advanced diagnostic testing, molecular profiling, and novel therapies are often more accessible in high-income healthcare systems or through comprehensive insurance coverage. In contrast, patients in lower-resource or impoverished settings m...
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. The Protocol has been gaining rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2026, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or canc...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 700 Patients (2026)

By Editorial Team
Image
Medically Reviewed by: OneDayMD Editorial Team | Last Updated: May 2026 Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Table of Contents: Editor's Preface Introduction Fenbendazole and Iverme...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2026 Update)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2026)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Dr. William Makis's Recommended Ivermectin Dosages for Cancer (2026)

By Editorial Team
Image
Last revised: June 2026 Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Ivermectin combined with benzimidazoles (fenbendazole, mebendazole) represents an emerging area of repurposed oncology pharmacology. All protocols require physician supervision. Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dos...
Read more

Fenbendazole and Ivermectin for Stage 4 Pancreatic Cancer: A Compilation of Case Reports and Mechanistic Insights (2026)

By Editorial Team
Image
OneDayMD  |  Integrative Oncology Review ISSN (Online) pending  •  Volume 1, Issue 1  •  Published: 10 August 2025  •  Updated: 15 June 2026 Case Series & Mechanistic Review Compiled tumour marker responses, radiologic outcomes, and mechanisms of anti-cancer action across an international patient cohort Last updated: 15 June 2026 DOI: pending  •  Cite as: OneDayMD Editorial Team. Antiparasitic Drug Repurposing in Stage 4 PDAC: A Compiled Case Series of 28 Patients. OneDayMD Integr Oncol Rev. 2025;1(1). Updated June 2026. Evidence Classification All case reports in this series represent CEBM Level 4–5 evidence (case reports and expert opinion). This compilation is hypothesis-generating. No randomised controlled trials of ivermectin, fenbendazole, or mebendazole for pancreati...
Read more

Archive

Show more